A
2.43
0.39 (19.12%)
| Previous Close | 2.04 |
| Open | 2.11 |
| Volume | 1,429,804 |
| Avg. Volume (3M) | 372,203 |
| Market Cap | 47,351,468 |
| Price / Book | 2.19 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -2.31 |
| Current Ratio (MRQ) | 3.59 |
| Operating Cash Flow (TTM) | -21.89 M |
| Levered Free Cash Flow (TTM) | -12.17 M |
| Return on Assets (TTM) | -138.27% |
| Return on Equity (TTM) | -3,159.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Annovis Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
0.9
| Analyst Consensus | 1.0 |
| Insider Activity | 5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.90 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.45% |
| % Held by Institutions | 13.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lokken Investment Group Llc | 31 Mar 2025 | 29,235 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Canaccord Genuity, 599.59%) | Buy |
| Median | 14.50 (496.71%) | |
| Low | 12.00 (HC Wainwright & Co., 393.83%) | Buy |
| Average | 14.50 (496.71%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.38 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jun 2025 | 12.00 (393.83%) | Buy | 3.06 |
| Canaccord Genuity | 15 May 2025 | 17.00 (599.59%) | Buy | 1.69 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WALSH ANDREW | 2.83 | - | 500 | 1,415 |
| Aggregate Net Quantity | 500 | |||
| Aggregate Net Value ($) | 1,415 | |||
| Aggregate Avg. Buy ($) | 2.83 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WALSH ANDREW | Officer | 16 Jun 2025 | Acquired (+) | 500 | 2.83 | 1,415 |
| Date | Type | Details |
|---|---|---|
| 26 Jun 2025 | Announcement | Annovis to Attend the AAIC 2025 with Four Poster Presentations |
| 19 Jun 2025 | Announcement | Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance |
| 05 Jun 2025 | Announcement | Annovis to Host Webinar and Live Q&A on June 24, 2025 |
| 13 May 2025 | Announcement | Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results |
| 29 Apr 2025 | Announcement | Annovis Bio Appoints Hui Liu as Director of Biostatistics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |